{
  "patent_families": {
    "ventus_therapeutics": {
      "WO2024137752A1": {
        "title": "Azepino[4,5-b]indolone inhibitors",
        "assignee": "Ventus Therapeutics U.S., Inc.",
        "priority_date": "2022-12-20",
        "filing_date": "2023-12-20",
        "publication_date": "2024-06-27",
        "core_scaffold": "Azepino[4,5-b]indolone derivatives",
        "vent03_link": "Explicit mention of VENT-03 in patent text",
        "potency_data": {
          "biochemical_ic50": "<0.001 µM (sub-nanomolar)",
          "cellular_ic50": "<0.001 µM",
          "high_potency_examples": [32, 33, 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61]
        },
        "preferred_embodiments": {
          "X_and_R4": "Halo, particularly chloro",
          "R7": "Methyl",
          "specific_compounds": "Listed in Embodiments 57, 58, and 59"
        },
        "significance": "Most critical patent for VENT-03 identification"
      },
      "WO2023183275A1": {
        "title": "Hexahydropyrido[4,3-b]indolyl ketone derivatives",
        "assignee": "Ventus Therapeutics U.S., Inc.",
        "priority_date": "2022-03-21",
        "publication_date": "2023-09-28",
        "core_scaffold": "Hexahydropyrido[4,3-b]indolyl ketone derivatives",
        "vent03_link": "No explicit mention found",
        "significance": "Earlier series, likely precursor to clinical candidate"
      }
    },
    "prior_art": {
      "WO2019153002A1": {
        "title": "Tetrahydro-pyrido[4,3-b]indole inhibitors",
        "priority_date": "2018-02-05",
        "core_scaffold": "2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole derivatives",
        "specific_compounds": "1-(3,4-dihydro-1H-pyrido[4,3-b]indol-2(5H)-yl)-2-hydroxyethanones",
        "significance": "Prior art referenced in Ventus patents"
      }
    }
  },
  "patent_classification_codes": {
    "medicinal_preparations": {
      "A61K_31": "Medicinal preparations containing organic active ingredients",
      "A61K_31_40": "Indoles",
      "A61K_31_47": "Quinolines", 
      "A61K_31_41": "Five-membered N-heterocycles",
      "A61K_31_425": "Thiazoles",
      "A61K_31_505": "Pyrimidines"
    },
    "organic_chemistry": {
      "C07D_209": "Indoles",
      "C07D_215": "Quinolines",
      "C07D_231": "Pyrazoles",
      "C07D_249": "Triazoles",
      "C07D_277": "Thiazoles",
      "C07D_307": "Furans",
      "C07D_471": "Fused systems",
      "C07D_487": "Fused systems",
      "C07D_491": "Fused systems"
    },
    "therapeutic_activity": {
      "A61P_37": "Drugs for immunological or allergic disorders",
      "A61P_29": "Anti-inflammatory agents",
      "A61P_25": "Drugs for nervous system disorders",
      "A61P_35": "Antineoplastic agents"
    }
  },
  "filing_trends_detailed": {
    "2015": {
      "estimated_families": "5-10",
      "key_developments": "Post-discovery phase, initial academic filings"
    },
    "2016": {
      "estimated_families": "10-15", 
      "key_developments": "Increasing commercial interest"
    },
    "2017": {
      "estimated_families": "20-30",
      "key_developments": "Major players entering field"
    },
    "2018": {
      "estimated_families": "30-40",
      "key_developments": "Peak filing activity"
    },
    "2019": {
      "estimated_families": "25-35",
      "key_developments": "Sustained activity, diverse scaffolds"
    },
    "2020": {
      "estimated_families": "25-35",
      "key_developments": "Continued strong interest"
    },
    "2021": {
      "estimated_families": "20-30",
      "key_developments": "Optimization focus"
    },
    "2022": {
      "estimated_families": "15-25",
      "key_developments": "Clinical candidates emerging"
    },
    "2023": {
      "estimated_families": "15-25",
      "key_developments": "Clinical development focus"
    },
    "2024": {
      "estimated_families": "10-20",
      "key_developments": "Continued optimization, clinical results"
    }
  },
  "geographic_strategy": {
    "PCT_route": {
      "percentage": ">75%",
      "strategy": "International protection via WIPO",
      "advantages": ["Delayed national phase decisions", "Broad geographic coverage", "Cost efficiency"]
    },
    "national_phases": {
      "US": {
        "percentage": ">75%",
        "importance": "Primary market and innovation hub",
        "patent_term": "20 years from filing"
      },
      "EP": {
        "percentage": ">70%",
        "importance": "Major commercial market",
        "validation_countries": "Key EU markets"
      },
      "CN": {
        "percentage": ">50%",
        "importance": "Growing pharmaceutical market",
        "trend": "Increasing national phase entry"
      },
      "JP": {
        "percentage": ">50%",
        "importance": "Established pharmaceutical market",
        "characteristics": "High-value market for autoimmune therapies"
      }
    }
  },
  "fto_landscape": {
    "foundational_patents": {
      "university_of_texas": {
        "role": "Foundational cGAS-STING pathway discoveries",
        "licensing_strategy": "Often co-assigned or licensed to commercial entities",
        "risk_level": "High - broad foundational claims"
      }
    },
    "competitive_overlaps": {
      "indole_derivatives": {
        "companies": ["Novartis", "Merck"],
        "risk_level": "Medium - multiple players in same chemical space"
      },
      "pyrido_indoles": {
        "companies": ["Merck", "Ventus"],
        "risk_level": "Medium - overlapping scaffold claims"
      }
    },
    "novel_scaffolds": {
      "azepino_indolones": {
        "company": "Ventus",
        "risk_level": "Low - novel chemical space",
        "patent": "WO2024137752A1"
      }
    },
    "mitigation_strategies": [
      "Comprehensive FTO searches before clinical development",
      "Novel scaffold development",
      "Specific substitution patterns for design-around",
      "Licensing negotiations for foundational IP",
      "Geographic strategy optimization"
    ]
  }
}